Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
07:30am, Tuesday, 04'th Jun 2024
The obesity market is expected to reach $130 billion by 2030, benefiting companies like Eli Lilly and Novo Nordisk. Amgen, a biotech company, is experiencing innovation-fueled growth with impressive n
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
04:00pm, Monday, 03'rd Jun 2024
THOUSAND OAKS, Calif. , June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m.
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
09:00am, Monday, 03'rd Jun 2024
Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.
Where Will Amgen Be in 3 Years?
08:15am, Wednesday, 29'th May 2024
Amgen has some compelling late-stage programs in its pipeline. Growth is likely to accelerate as the biotech makes progress.
Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval
06:49pm, Tuesday, 28'th May 2024
Pharmaceutical regulators approved Amgen's AMGN, -1.85% Bkemv, a biosimilar to rare-disease treatment Soliris.
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
06:08pm, Tuesday, 28'th May 2024
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
09:00am, Tuesday, 28'th May 2024
Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS® (sotorasib) Plus Vectibix® (panitu
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 27'th May 2024
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
06:53am, Sunday, 26'th May 2024
Amgen has a promising entrant in the anti-obesity therapies space. Its candidate is in phase 2 trials, but there are already plans for phase 3.
Sell Alert: 2 Dividend Stocks To Sell In May And Go Away
11:03am, Friday, 24'th May 2024
The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the worst
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
07:00am, Friday, 24'th May 2024
Investing in Dow stocks is always a reasonable strategy for those who value the American economy. The Dow Jones is composed of 30 prominent publicly listed U.S. firms.
Amgen Stock: Poised To Break Out (Technical Analysis)
04:27pm, Tuesday, 21'st May 2024
Amgen Inc. stock is challenging the $320 resistance level after a recent uptrend. Technical indicators suggest short-term upward momentum and strong buying pressure. EPS growth outlook and robust pipe
7 Reliable Blue-Chip Stocks That Cannot Miss
09:44am, Tuesday, 21'st May 2024
If you're on the hunt for reliable blue-chip stocks to buy this month, look no further. Reliability is one of the most important factors when creating a winning investment strategy.
Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)
09:04pm, Monday, 20'th May 2024
Amgen, Inc. (NASDAQ:AMGN ) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
01:34pm, Monday, 20'th May 2024
Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have he
